{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:35:08Z","timestamp":1774125308357,"version":"3.50.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy against tuberculosis. In this study we measured the efficacies of rifapentine-containing intermittent drug regimens for preventive therapy using the Cornell mouse model of latent tuberculosis. We infected groups of mice intravenously with\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            and then treated them with isoniazid and pyrazinamide for 12 weeks according to the Cornell latency development protocol. After a 4-week interval of no treatment, experimental preventive therapy was administered by esophageal gavage for 12 or 18 weeks. After equilibration and dexamethasone amplification treatment, mouse organs were analyzed by quantitative colony counts to measure the effectiveness of therapy. Our results showed that once-weekly isoniazid plus rifapentine combination therapy for 18 weeks was an effective preventive regimen with sterilizing potency and bacillary load reduction comparable to those of daily isoniazid therapy for 18 weeks. Monotherapy with rifapentine weekly or fortnightly or with rifampin twice weekly for up to 18 weeks did not offer advantages in reducing bacillary load or in sterilizing organs compared to the effects of a placebo. These results with the Cornell mouse model indicate that once-weekly, short-course preventive therapy with isoniazid plus rifapentine is effective and may warrant investigation in humans with latent tuberculosis infection.\n          <\/jats:p>","DOI":"10.1128\/aac.43.9.2126","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:35:31Z","timestamp":1539045331000},"page":"2126-2130","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis"],"prefix":"10.1128","volume":"43","author":[{"given":"Eishi","family":"Miyazaki","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Center for Tuberculosis Research, Department of International Health,1"},{"name":"<!--label omitted: 2-->Department of Molecular Microbiology and Immunology, Johns Hopkins School of Hygiene and Public Health,2 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Tuberculosis Research, Department of International Health,1"},{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine,3 Baltimore, Maryland 21205-2179"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Bishai","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Tuberculosis Research, Department of International Health,1"},{"name":"<!--label omitted: 2-->Department of Molecular Microbiology and Immunology, Johns Hopkins School of Hygiene and Public Health,2 and"},{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine,3 Baltimore, Maryland 21205-2179"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.1995.03530020061033","article-title":"Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study.","volume":"274","author":"Antonucci G.","year":"1995","unstructured":"Antonucci G. Girardi E. Raviglione M. C. Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 274 1995 143 148","journal-title":"JAMA"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.7164\/antibiotics.34.1026","article-title":"Antibacterial activity of DL473, a new semisynthetic rifamycin derivative.","volume":"34","author":"Arioli V.","year":"1981","unstructured":"Arioli V. Berti M. Carniti G. Randisi E. Rossi E. Scotti R. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J. Antibiot. (Tokyo) 34 1981 1026 1029","journal-title":"J. Antibiot. (Tokyo)"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.7164\/antibiotics.37.1066","article-title":"Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit.","volume":"37","author":"Assandri A.","year":"1984","unstructured":"Assandri A. Ratti B. Christina T. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J. Antibiot. (Tokyo). 37 1984 1066 1069","journal-title":"J. Antibiot. (Tokyo)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"455P","DOI":"10.1111\/j.1365-2125.1978.tb04626.x","article-title":"Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin).","volume":"6","author":"Birmingham A. T.","year":"1978","unstructured":"Birmingham A. T. Coleman A. J. Orme M. L. S. Park B. K. Pearson N. J. Short A. H. Southgate P. J. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br. J. Clin. Pharmacol. 6 1978 455P 456P","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.5.7952564"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0962-8479(95)90534-0","article-title":"The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis.","volume":"76","author":"de Wit D.","year":"1995","unstructured":"de Wit D. Wootton M. Dhillon J. Mitchison A. The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber. Lung Dis. 76 1995 555 562","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0962-8479(92)90066-S","article-title":"Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis.","volume":"73","author":"Dhillon J.","year":"1992","unstructured":"Dhillon J. Dickinson J. M. Guy J. A. Ng T. K. Mitchison D. A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber. Lung Dis. 73 1992 116 123","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.552"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-3879(68)80016-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0041-3879(87)90026-2","article-title":"In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.","volume":"68","author":"Dickinson J. M.","year":"1987","unstructured":"Dickinson J. M. Mitchison D. A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68 1987 113 118","journal-title":"Tubercle"},{"key":"e_1_3_2_12_2","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis: a general review.","volume":"17","author":"Ferebee S. H.","year":"1970","unstructured":"Ferebee S. H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv. Tuberc. Res. 17 1970 28 106","journal-title":"Adv. Tuberc. Res."},{"key":"e_1_3_2_13_2","unstructured":"Gordin\n              F. M.\n          and the CPCRA 004\/ACTG 177 Investigators.\n          Preliminary analysis of short-course preventive therapy for tuberculosis in HIV-infected adults.\n          Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections\n          1998"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.5.9709072"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.","volume":"351","author":"Halsey N. A.","year":"1998","unstructured":"Halsey N. A. Coberly J. S. Desormeaux J. Losikoff P. Atkinson J. Moulton L. H. Cantave M. Johnson M. Davis H. Geiter L. Johnson E. Huebner R. Boulos R. Chaisson R. E. Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351 1998 786 791","journal-title":"Lancet"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.3.626"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.","volume":"145","author":"Hong Kong Chest Service and British Medical Research Council","year":"1992","unstructured":"Hong Kong Chest Service and British Medical Research Council A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 145 1992 36 41","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(91)90017-M"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/ajrccm\/140.5.1189","article-title":"Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.","volume":"140","author":"Lecoeur H. F.","year":"1989","unstructured":"Lecoeur H. F. Truffot-Pernot C. Grosset J. H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140 1989 1189 1193","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.123.3.445"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.85"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2073"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","article-title":"Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.","volume":"12","author":"Mwinga A.","year":"1998","unstructured":"Mwinga A. Hosp M. Godfrey-Faussett P. Quigley M. Mwaba P. Mugala B. N. Nyirenda O. Luo N. Pobee J. Elliott A. M. McAdam K. P. Porter J. D. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 12 1998 2447 2457","journal-title":"AIDS"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0962-8479(92)90033-G","article-title":"HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention.","volume":"73","author":"Narain J. P.","year":"1992","unstructured":"Narain J. P. Raviglione M. C. Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber. Lung Dis. 73 1992 311 321","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(98)01216-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.","volume":"320","author":"Selwyn P. A.","year":"1989","unstructured":"Selwyn P. A. Hartel D. Lewis V. A. Schoenbaum E. E. Vermund S. H. Klein R. S. Walker A. T. Friedland G. H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320 1989 545 550","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_28_2","first-page":"411","article-title":"Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.","volume":"1","author":"Tam C. M.","year":"1997","unstructured":"Tam C. M. Chan S. L. Lam C. W. Dickinson J. M. Mitchison D. A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int. J. Tuberc. Lung Dis. 1 1997 411 416","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9707037"},{"key":"e_1_3_2_30_2","first-page":"143","article-title":"A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis.","volume":"43","author":"Tuberculosis Chemotherapy Centre","year":"1970","unstructured":"Tuberculosis Chemotherapy Centre A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull W. H. O. 43 1970 143","journal-title":"Bull W. H. O."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803053381001"},{"issue":"2","key":"e_1_3_2_32_2","first-page":"A255","article-title":"Design of U.S. Public Health Service (U.S.P.H.S) Study 22: a trial of once weekly isoniazid (INH) and rifapentine (Rpt) in the continuation phase of TB treatment.","volume":"155","author":"Vernon A.","year":"1997","unstructured":"Vernon A. Villarino E. Geiter L. O\u2019Brien R. Design of U.S. Public Health Service (U.S.P.H.S) Study 22: a trial of once weekly isoniazid (INH) and rifapentine (Rpt) in the continuation phase of TB treatment. Am. J. Respir. Crit. Care Med. 155 Part 2 1997 A255","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.","volume":"337","author":"Whalen C. C.","year":"1997","unstructured":"Whalen C. C. Johnson J. L. Okwera A. Hom D. L. Huebner R. Mugyenyi P. Mugerwa R. D. Ellner J. J. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N. Engl. J. Med. 337 1997 801 808","journal-title":"N. Engl. J. Med."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.9.2126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.9.2126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:33:27Z","timestamp":1645461207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.9.2126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1128\/AAC.43.9.2126"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.9.2126","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]},"assertion":[{"value":"1999-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}